



## MEDICAL TIPS

**CILNIBLU Tablets**

**Issue II, No. 8, 2023**

### **Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers: A Meta-Analysis of Randomized Controlled and Retrospective Studies**

*Srivathsan M et al; Cureus. 2022; 14(8).*

- Most patients with chronic kidney disease (CKD) suffer from hypertension, showing a close association.
- Hypertension and CKD can cause mutual deterioration, and the therapeutic outcomes of hypertension are closely related to renal function.
- The present meta-analysis found that the L/N-type calcium channel blocker (CCB) Cilnidipine significantly lowered the urinary protein excretion (UPE) and urinary protein/creatinine ratio (UPCR) without increasing serum creatinine (SCr) or decreasing estimated glomerular filtration rate (eGFR) as compared to L-type CCBs.
- Treatment with Cilnidipine was found to be more effective in reducing proteinuria or preventing its progression.

**Cilnidipine was advantageous in improving kidney function in addition to its role in the treatment of hypertension.**

